TYK2 and psoriasis vulgaris: Recently, oral deucravacitinib, a selective inhibitor of tyrosine kinase 2 (TYK2, a member of the JAK family), was shown to lead to larger improvements in symptom severity for patients with moderate‐to‐severe plaque psoriasis than oral Apremilast, the current standard of care.2, 3